REVIEW PAPER
Extrahepatic manifestations of hepatitis C virus infection in the oral cavity
1
Institute of Literary Studies and Linguistics, Jan Kochanowski University, Kielce, Poland
2
Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
3
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
4
Ophthalmic Clinic of the Voivodeship Hospital, Kielce, Poland
Submission date: 2023-12-15
Final revision date: 2024-08-24
Acceptance date: 2024-10-01
Publication date: 2025-09-30
Corresponding author
Michał Brzdęk
Michał Brzdęk Department of Infectious Diseases Collegium Medicum Jan Kochanowski University Kielce, Poland
Michał Brzdęk Department of Infectious Diseases Collegium Medicum Jan Kochanowski University Kielce, Poland
Medical Studies 2025;41(3):172-178
KEYWORDS
hepatitis C viruschronic hepatitis Cextrahepatic manifestationslichen planusxerostomiaperiodontal disease
TOPICS
ABSTRACT
According to data from the World Health Organization (WHO), the number of people actively infected with hepatitis C virus (HCV) in the world currently reaches 50 million. In the last few years, there has been a revolution in the treatment of chronic hepatitis C (CHC) and now safe interferon-free regimens based on drugs with direct-acting antivirals (DAA) are available in the treatment of HCV infections, the effectiveness of which exceeds 95%. As a result, according to WHO forecasts, it is possible to eliminate HCV infection by 2030. A necessary condition to achieve this goal is the diagnosis of the disease in patients unaware of the infection. Chronic HCV infection can lead to extrahepatic manifestations, including changes in the oral mucosa such as xerostomia, lichen planus, or periodontal diseases. The aim of this publication is to draw attention to the extrahepatic symptoms with which a patient infected with HCV may present to a dentist.
REFERENCES (37)
1.
Bukh J. The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol. 2016 Oct; 65 (1 Suppl): S2-S21.
2.
Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014 Jul; 20(28): 9270-9280.
3.
Tibbs CJ. Methods of transmission of hepatitis C. J Viral Hepat. 1995; 2(3): 113-119.
5.
Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 Feb; 14(2): 122-132.
6.
Tomasiewicz K, Flisiak R, Jaroszewicz J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Zarębska-Michaluk D. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023. Clin Exp Hepatol. 2023; 9(1): 1-8.
7.
Brzdęk M, Zarębska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J Gastroenterol. 2023 Feb; 29(6): 949-966.
8.
Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts - 2017. Clin Exp Hepatol. 2017; 3(2): 47-55.
9.
Flisiak R, Zarębska-Michaluk D, Jaroszewicz J, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Pabjan P, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Belica-Wdowik T, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Simon K, Pawłowska M. Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. Pol Arch Med Wewn. 2020 Feb; 130: 163-172.
10.
Dybowska D, Zarębska-Michaluk D, Rzymski P, Berak H, Lorenc B, Sitko M, Dybowski M, Mazur W, Tudrujek-Zdunek M, Janocha-Litwin J, Janczewska E, Klapaczyński J, Parfieniuk-Kowerda A, Piekarska A, Sobala-Szczygieł B, Dobrowolska K, Pawłowska M, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders. World J Gastroenterol. 2023 Jul; 29(25): 4085-4098.
11.
Tronina O, Brzdęk M, Zarębska-Michaluk D, Lorenc B, Janocha-Litwin J, Berak H, Sitko M, Dybowska D, Mazur W, Tudrujek-Zdunek M, Janczewska E, Klapaczyński J, Dobracki W, Parfieniuk-Kowerda A, Krygier R, Socha Ł, Flisiak R. Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure. Clin Exp Hepatol. 2023 Dec; 9(4): 320-334.
12.
Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020 Mar; 40(3): 522-559.
13.
Flisiak R, Halota W, Tomasiewicz K, Kostrzewska K, Razavi HA, Gower EE. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol. 2015 Jan; 27(1): 70-76.
14.
Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016 May; 10(3): 415-423.
15.
Carrozzo M, Scally K. Oral manifestations of hepatitis C virus infection. World J Gastroenterol. 2014 Jun; 20(24): 7534-7543.
16.
Garbin CAS, de Souza NP, de Vasconcelos RR, Garbin AJI, Villar LM. Hepatitis C virus and dental health workers: an update. Oral Health Prev Dent. 2014; 12(4): 313-321.
17.
Romano C, Cuomo G, Ferrara R, Del Mastro A, Esposito S, Sellitto A, Adinolfi LE. Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Rev Clin Immunol. 2018 Dec; 14(12): 1089-1099.
18.
Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016 Jun; 150(7): 1599-1608.
19.
Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, Callard P, Beaugrand M. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339: 321-323.
20.
Ubertalli Ape V, Pellicano R, Smedile A, Bertolusso G, Conrotto D, Arduino P, Carrozzo M. Oral health status and salivary function in Italian patients with HCV and HBV infection. Oral Dis. 2006; 12 (Suppl 1): 8.
21.
Songtanin B, Nugent K. Burden, outcome, and comorbidities of extrahepatic manifestations in hepatitis C virus infection. Biology (Basel). 2022 Dec; 12(1): 23.
22.
Arrieta JJ, Rodríguez-Iñigo E, Ortiz-Movilla N, Bartolomé J, Pardo M, Manzarbeitia F, Oliva H, Macías DM, Carreño V. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol. 2001 Jan; 158(1): 259-264.
23.
Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R, Manthorpe R, Tabery H, Widell A, Lindgren S. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren’s syndrome and hepatitis C in Swedish patients. J Intern Med. 1999 Feb; 245(2): 127-132.
24.
Millsop JW, Wang EA, Fazel N. Etiology, evaluation, and management of xerostomia. Clin Dermatol. 2017 Sep; 35(5): 468-476.
25.
Panov V, Krasteva A. Oral health in patients with liver diseases. J IMAB. 2011 Dec; 17(2): 140-142.
26.
Mokni M, Rybojad M, Puppin D Jr, Catala S, Venezia F, Djian R, MOrel P. Lichen planus and hepatitis C virus. J Am Acad Dermatol. 1991 May; 24(5): 792.
27.
Zarebska-Michaluk DA, Lebensztejn DM, Kryczka WM, Skiba E. Extrahepatic manifestations associated with chronic hepatitis C infections in Poland. Adv Med Sci. 2010; 55(1): 67-73.
28.
Mester A, Lucaciu O, Ciobanu L, Apostu D, Ilea A, Campian RS. Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP. Bosn J Basic Med Sci. 2018 Aug; 18(3): 217-223.
29.
Carozzo M. Oral diseases associated with hepatitis C virus infection. Part 2. Lichen planus and other diseases. Oral Dis. 2008; 14: 217-228.
30.
Wiznia LE, Laird ME, Franks AG Jr. Hepatitis C virus and its cutaneous manifestations: treatment in the direct‐acting antiviral era. J Eur Acad Dermatol Venereol. 2017 Aug; 31(8): 1260-1270.
32.
Han P, Sun D, Yang J. Interaction between periodontitis and liver diseases. Biomed Rep. 2016 Sep; 5(3): 267-276.
33.
Coates EA, Brennan D, Logan RM, Goss AN, Scopacasa B, Spencer AJ, Gorkic E. Hepatitis C infection and associated oral health problems. Aust Dent J. 2000 Jun; 45(2): 108-114.
34.
Henderson L, Muir M, Mills PR, Spence E, Fox R, McCruden EA, Bagg J. Oral health of patients with hepatitis C virus infection: a pilot study. Oral Dis. 2001 Sep; 7(5): 271-275.
35.
Sulka A, Simon K, Piszko P, Kalecińska E, Dominiak M. Oral mucosa alterations in chronic hepatitis and cirrhosis due to HBV or HCV infection. Bull Group Int Rech Sci Stomatol Odontol. 2006 Mar; 47(1): 6-10.
36.
Olczak-Kowalczyk D, Pawłowska J, Kowalczyk W. Oral health status in children with chronic liver disease. J Stoma. 2011; 64: 760-774.
37.
Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV extrahepatic manifestations. J Clin Transl Hepatol. 2019 Mar 28; 7(2): 172-182.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
